文献速递妇产影像泌尿生殖US

O-RADS US:各分类恶性肿瘤率的系统评价与Meta分析

O-RADS US: A Systematic Review and Meta-Analysis of Category-specific Malignancy Rates.
PubMed 文献 · Radiology · 2023-01-01

该系统评价与Meta分析纳入18项研究共11605例患者和11818个卵巢-附件病变,评估O-RADS US各评分对应的恶性肿瘤率及4和5类联合诊断效能。O-RADS 1类未见恶性病变,2至5类的汇总恶性率分别为0.6%、3.9%、43.5%和87.3%,4和5类联合诊断的汇总敏感度为95.6%、特异度为76.6%。

要点

  • O-RADS 1类未见恶性病变,2类恶性率0.6%,3类3.9%,4类43.5%,5类87.3%。
  • O-RADS 4和5类联合预测恶性病变的汇总敏感度为95.6%,特异度为76.6%。
  • 各O-RADS US评分提供的恶性概率与O-RADS风险分层系统所列相符。

核心结论

  • 各O-RADS US评分提供了O-RADS风险分层系统所设定的恶性病变概率;将O-RADS US 4和5类联合作为恶性预测指标时,O-RADS US显示出高敏感度和中等特异度。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE和Web of Science数据库自建库至2023年1月27日的文献,最终纳入18项研究,共11605例患者和11818个卵巢-附件病变,其中恶性2996个(25.4%)、良性8822个(74.6%)。

诊断标准与关键数值

  • O-RADS 1类未报告恶性病变。
  • O-RADS 2类汇总恶性率为0.6%(95% CI:0.3,1.0)。
  • O-RADS 3类汇总恶性率为3.9%(95% CI:2.5,5.4)。
  • O-RADS 4类汇总恶性率为43.5%(95% CI:33.8,53.2)。
  • O-RADS 5类汇总恶性率为87.3%(95% CI:83.0,91.7);O-RADS 4和5类联合诊断恶性病变的汇总敏感度为95.6%(95% CI:94.0,97.2)、特异度为76.6%(95% CI:70.4,82.7)。

临床应用与阅片要点

  • 日常阅片中可依据O-RADS US评分对应的汇总恶性率(1类未见恶性、2类0.6%、3类3.9%、4类43.5%、5类87.3%)向临床传达风险。
  • O-RADS 4和5类联合用于恶性预测时汇总敏感度为95.6%、特异度为76.6%,报告时可引用该诊断效能数据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Ovarian-Adnexal Reporting and Data System (O-RADS) US provides a standardized method with which to stratify lesions into risk of malignancy categories, which is crucial for proper management. Purpose To perform a systematic review and meta-analysis to estimate malignancy rates for each O-RADS US score and evaluate the diagnostic performance of combined O-RADS US scores 4 and 5 in the diagnosis of malignancy. Materials and Methods A systematic literature search from the inception of the MEDLINE, EMBASE, and Web of Science databases through January 27, 2023, was performed for articles that reported using the O-RADS US stratification system and included malignancy rates per each O-RADS score. Bivariate random-effects models were used to determine the pooled malignancy rates for each O-RADS US score and to obtain summary estimates of the diagnostic performance of combined O-RADS US scores 4 and 5 in the diagnosis of malignant lesions. Results The final analysis included 18 studies consisting of 11 605 patients and 11 818 ovarian-adnexal lesions, with 2996 malignant (25.4%) and 8822 benign (74.6%) lesions. No malignant lesions were reported in O-RADS 1 category. The pooled percentages of malignancy were 0.6% (95% CI: 0.3, 1.0) for O-RADS 2, 3.9% (95% CI: 2.5, 5.4) for O-RADS 3, 43.5% (95% CI: 33.8, 53.2) for O-RADS 4, and 87.3% (95% CI: 83.0, 91.7) for O-RADS 5. The pooled sensitivity and specificity of combined O-RADS scores 4 and 5 in the diagnosis of malignant lesions were 95.6% (95% CI: 94.0, 97.2) and 76.6% (95% CI: 70.4, 82.7), respectively. Conclusion Each O-RADS US score provided the intended probability of malignant lesions as outlined by the O-RADS risk stratification system. When O-RADS US scores 4 and 5 were combined as a predictor for malignancy, O-RADS US showed a high sensitivity and moderate specificity. Clinical trial registration no. CRD42022352166 © RSNA, 2023 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lee S, Lee JE, Hwang JA, et al. O-RADS US: A Systematic Review and Meta-Analysis of Category-specific Malignancy Rates. Radiology. 2023. PMID: 37642566. doi:10.1148/radiol.223269

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。